Clinical trials: Antithrombotic
Acute Coronary Syndrome
Bleeding Risk Assessment System for Antithrombotic Therapy of ACS
Antithrombotic therapy is the cornerstone of the management of patients with acute coronary syndrome (ACS), which result in lower risk of mortality and ischemic events.
- Trial name
- NCT04162808
- Where
- China
- Volunteers
- 6,379 people
- Sponsor
- Beijing Anzhen Hospital
Traumatic Intracranial Hemorrhage, Brain Injuries
Mild Traumatic Brain Injury and the Risk for Traumatic Intracranial Hemorrhage
Management of traumatic brain injuries causes significant efforts on emergency departments (ED) and overall health care. Patients on antithrombotic treatment with even minor trauma to the head, although without significant…
- Trial name
- NCT05609721
- Testing
- no intervention, only observational study
- Where
- Sweden
- Volunteers
- 2,044 people
- Sponsor
- Umeå University
Coronary Artery Disease
Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease
Long-term aspirin (ASA) is the standard recommended antithrombotic therapy in patients with stable coronary artery disease (CAD), especially following stenting (Class I, Level A).
- Trial name
- AQUATIC (NCT04217447)
- Testing
- OAC + Aspirin 100mg od
- Where
- 51 sites in France
- Volunteers
- 874 people
- Sponsor
- University Hospital, Brest
Hemophilia A
Long-term Anticoagulation in a Patient With Severe Hemophilia A
To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII)…
- Trial name
- HAAC (NCT07314983)
- Where
- France
- Volunteers
- 1 people
- Sponsor
- University Hospital, Strasbourg, France
Acute Myocardial Infarction, Coronary Stent Thrombosis, Antithrombotic Therapy
The MATRIX OCT Substudy
Residual thrombosis of stent struts may occur after the end of primary angioplasty and determine distal embolization and further myocardial damage.
- Trial name
- NCT01971788
- Testing
- Optical Coherence Tomography of the infarct related artery
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- S.M. Misericordia Hospital
Venous Thromboembolism
Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
The purpose of this study is to evaluate whether the effect of the two new anticoagulants, Dabigatran and Rivaroxaban, can be reversed by non-specific and specific inhibitors.
- Trial name
- REVNEWANTICO (NCT01210755)
- Testing
- Rivaroxaban, Dabigatran, Dabigatran; Rivaroxaban
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Cerebral Hemorrhage
REstart or STop Antithrombotic Randomised Trial in France
RESTART- fr is a randomised controlled trial for adults surviving spontaneous intracerebral haemorrhage who had taken an antithrombotic drug (i.e.
- Trial name
- RESTART-Fr (NCT02966119)
- Testing
- Clopidogrel or Aspirin and/or Dypyridamole
- Where
- France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Lille
Peripheral Arterial Disease
Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.
Rationale: Peripheral arterial disease (PAD) is a common presentation of atherosclerosis. For the prevention of adverse events related to arterial thrombosis in PAD patients, clopidogrel is recommended.
- Trial name
- GENPAD (NCT04619927)
- Testing
- Direct CYP2C19 genotyping, CYP2C19 genotyping at the end of the study, Poor metabolisers
- Where
- 11 sites in Netherlands
- Volunteers
- 2,276 people
- Sponsor
- Radboud University Medical Center
Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation)
Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial
Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
- Conditions
- Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation), Aspirin, DAPT(Dual Antiplatelet Therapy)
- Trial name
- NCT06007222
- Testing
- Aspirin group, Non-antithrombotic group
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- OCEAN-SHD Study Group
Coronary Syndrome
Incidence, Clinical Characteristics and Prognosis of Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Spontaneous Coronary Reperfusion in the Modern Antithrombotic Strategy Area
The rapid and complete restoration of coronary flow is a key issue in the management of STEMI. Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy associated with antithrombotic drugs.
- Trial name
- STEMI (NCT04881552)
- Where
- France
- Volunteers
- 302 people
- Sponsor
- University Hospital, Montpellier
Venous Thromboembolic Disease, Deep Vein Thrombosis
Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
The rate of venous thromboembolic events in trauma patients at high risk for deep vein thrombosis and pulmonary embolism receiving low dose unfractionated heparin every 8 hours will be equivalent or less than a similar group of…
- Conditions
- Venous Thromboembolic Disease, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT01729559
- Testing
- 5000 Units unfractionated Heparin Q 8 hr, 30mg enoxaparin Q12 hr
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Scripps Health
Acute ST Elevation Myocardial Infarction
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
The purpose of this study is to compare unfractionated heparin (UFH) and bivalirudin in the performance and subsequent outcomes of Primary percutaneous coronary intervention. This will be a pragmatic trial.
- Trial name
- HEAT-PPCI (NCT01519518)
- Testing
- unfractionated heparin, Bivalirudin
- Where
- United Kingdom
- Volunteers
- 1,829 people
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Atherosclerotic Cardiovascular Disease (ASCVD), Secondary Prevention
Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients
Elderly patients with cardiovascular disease face a high risk of both thrombotic and bleeding events when receiving antithrombotic therapy.
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Secondary Prevention, Cardiovascular Diseases
- Trial name
- LAPIS (NCT07542860)
- Where
- China
- Volunteers
- 5,448 people
- Sponsor
- Peking University First Hospital
COVID-19
COVID-19 Antithrombotic Rivaroxaban Evaluation
There are several ways in which the COVID-19 pandemic may affect the prevention and management of thrombotic and thromboembolic disease, either direct effect or the indirect effects of infection, such as through severe illness…
- Trial name
- CARE (NCT04757857)
- Testing
- Rivaroxaban 10 mg
- Where
- 36 sites in Brazil
- Volunteers
- 660 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
Cerebral Hemorrhage, Atrial Fibrillation
Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation
There is a marked lack of evidence on the optimal prevention of ischaemic stroke in patients with atrial fibrillation and a recent intracerebral haemorrhage (ICH) during treatment with oral anticoagulation.
- Trial name
- APACHE-AF (NCT02565693)
- Testing
- Apixaban, Aspirin, Carbasalate calcium
- Where
- 16 sites in Netherlands
- Volunteers
- 101 people
- Sponsor
- UMC Utrecht
Atrial Fibrillation, Coronary Artery Disease
Antithrombotic Strategy for AF Patients With High Risk CAD
Anticoagulation therapy is recommended for patients with atrial fibrillation (AF) in order to prevent ischemic stroke and systemic embolism.
- Trial name
- ADAPT AFFIRM (NCT06866665)
- Testing
- Anticoagulation Monotherapy, Combination therapy
- Volunteers
- 1,400 people
- Sponsor
- Yonsei University
Atrial Fibrillation
REGistry of Long-term AnTithrombotic TherApy-2
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation
- Trial name
- REGATTA-2 (NCT04347187)
- Testing
- Anticoagulants
- Where
- Russia
- Volunteers
- 2,000 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF)
Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)
It is a multi-center randomized clinical trial (RCT) which will enroll 3746 patients with acute coronary syndrome (ACS) concomitant non-valvular atrial fibrillation (NVAF) and undergoing new generation drug eluting stent (DES)…
- Trial name
- NCT03234114
- Testing
- Triple antithrombotic therapy, Dual antithrombotc therapy-1, Dual antithrombotc therapy-2
- Where
- China
- Volunteers
- 3,746 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Aortic Valve Disease, Myocardial Infarction
Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial
The purpose of this study is to compare aspirin + clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve implantation (TAVI) for the prevention of major ischemic events [myocardial…
- Conditions
- Aortic Valve Disease, Myocardial Infarction, Stroke
- Trial name
- ARTE (NCT01559298)
- Testing
- Aspirin (80 mg/d) + clopidogrel (75 mg/d), Aspirin
- Where
- 2 sites in Canada
- Volunteers
- 178 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Acute Coronary Syndrome
Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia
The purpose of this study is to describe the short-and long-tern (i.e. up to 2 years following the index event) AMPs in patients hospitalized for an acute coronary syndrome (i.e.
- Trial name
- EPICOR ASIA (NCT01361386)
- Where
- 108 sites in China, India and 5 more
- Volunteers
- 13,011 people
- Sponsor
- AstraZeneca